Search
Search
Editorially Independent Content, Supported With Advertising From Genentech
Carl Regillo, MD; Maria Berrocal, MD; Prof. David Keegan; and Tamer Mahmoud, MD, PhD
Show Description +
In this episode of Innovations in Surgical Retina, Carl Regillo, MD, demonstrates the surgical technique for implanting the Port Delivery System (PDS), which recently completed phase 3 studies for extended delivery of ranibizumab (Lucentis, Genentech) for patients with neovascular AMD. Dr. Regillo and the panel discuss patient eligibility and selection, and the great potential to reduce treatment burden for patients and their care providers.
Posted: 10/22/2021
Carl Regillo, MD; Maria Berrocal, MD; Prof. David Keegan; and Tamer Mahmoud, MD, PhD
In this episode of Innovations in Surgical Retina, Carl Regillo, MD, demonstrates the surgical technique for implanting the Port Delivery System (PDS), which recently completed phase 3 studies for extended delivery of ranibizumab (Lucentis, Genentech) for patients with neovascular AMD. Dr. Regillo and the panel discuss patient eligibility and selection, and the great potential to reduce treatment burden for patients and their care providers.
Posted: 10/22/2021
Please log in to leave a comment.